Figure 3.

Dose effects of RTD-1 on airway neutrophilia, neutrophil activation, and microvascular disruption. To assess the dose response of RTD-1, mice received subcutaneous pretreatment with 0, 0.2, 1, 5, or 25 μg/ml RTD-1 0.5 hour before 1 μg intranasal LPS instillation. BAL fluid (BALF) was evaluated for (A) total, (B) differential, (C) peroxidase (POD) activity, (D) global matrix metalloproteinase (MMP) activity, and (E) total protein; n =  6 mice per group; mean (±95% confidence interval); treatment compared with control by one-way ANOVA with the Bonferroni post test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. MAC = macrophages; RFU = relative fluorescent units; WBCs = white blood cells.